• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page

Karyopharm - oncology





































Well…it’s official over. Worst decision of my career to come to this train wreck. Terrible decision by SC to make the “changes” she made. TS is not a leader and no one will follow him. You think sales are soft now…it will only get worse with these changes.

People have already checked out mentally.

Amgen legacy destroys another company…
 




Well…it’s official over. Worst decision of my career to come to this train wreck. Terrible decision by SC to make the “changes” she made. TS is not a leader and no one will follow him. You think sales are soft now…it will only get worse with these changes.

People have already checked out mentally.

Amgen legacy destroys another company…
Shut up bitch